Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice

Vaccine

Volumn 31, Issue 11, 2013, Pages 1540-1547

  Huret, Christophe ^a,b,c   Desjardins, Delphine ^a,b,c,d   Miyalou, Mathilde ^a,b,c   Levacher, Béatrice ^a,b,c   Amadoudji Zin, Martin ^a,b,c   Bonduelle, Olivia ^e   Combadière, Béhazine ^e   Dalba, Charlotte ^f   Klatzmann, David ^a,b,c,d   Bellier, Bertrand ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c Unit of Dermatology   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSERM   (France)

^f Epixis SA   (France)

Author keywords

DNA; HCV vaccine; Neutralizing antibody; Prime boost; VLP

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; PLASMID DNA;

ARTICLE; CELLULAR IMMUNITY; EX VIVO STUDY; GENE TARGETING; HEPATITIS C; IMMUNIZATION; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ANIMALS; B-LYMPHOCYTES; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; LEUKEMIA VIRUS, MURINE; MICE; MICE, INBRED C57BL; PLASMIDS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL HEPATITIS VACCINES;

EID: 84874444963     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.025     Document Type: Article

References (26)

1. Ciuffreda D., Kim A.Y. Update on hepatitis C virus-specific immunity. Curr Opin HIV AIDS 2011, 6(6):559-565.
2. Edwards V.C., Tarr A.W., Urbanowicz R.A., Ball J.K. The role of neutralizing antibodies in hepatitis C virus infection. J Gen Virol 2012, 93(Pt 1):1-19.
3. Torresi J., Johnson D., Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011, 54(6):1273-1285.
4. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003, 100(11):6753-6758.
5. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007, 104(20):8427-8432.
6. Denis J., Majeau N., Acosta-Ramirez E., Savard C., Bedard M.C., Simard S., et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007, 363(1):59-68.
7. Mihailova M., Boos M., Petrovskis I., Ose V., Skrastina D., Fiedler M., et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 2006, 24(20):4369-4377.
8. Netter H.J., Macnaughton T.B., Woo W.P., Tindle R., Gowans E.J. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 2001, 75(5):2130-2141.
9. Bellier B., Dalba C., Clerc B., Desjardins D., Drury R., Cosset F.L., et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006, 24(14):2643-2655.
10. Bellier B., Huret C., Miyalou M., Desjardins D., Frenkiel M.P., Despres P., et al. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 2009, 27(42):5772-5780.
11. Desjardins D., Huret C., Dalba C., Kreppel F., Kochanek S., Cosset F.L., et al. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med 2009, 11(4):313-325.
12. Garrone P., Fluckiger A.C., Mangeot P.E., Gauthier E., Dupeyrot-Lacas P., Mancip J., et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011, 3(94):94ra71.
13. Torrieri-Dramard L., Lambrecht B., Ferreira H.L., Van den Berg T., Klatzmann D., Bellier B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther 2011, 19(3):602-611.
14. Dalba C., Bellier B., Kasahara N., Klatzmann D. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 2007, 15(3):457-466.
15. Loudon P.T., Yager E.J., Lynch D.T., Narendran A., Stagnar C., Franchini A.M., et al. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 2010, 5(6):e11021.
16. Winstone N., Wilson A.J., Morrow G., Boggiano C., Chiuchiolo M.J., Lopez M., et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol 2011, 85(18):9578-9587.
17. Yerly D., Heckerman D., Allen T.M., Chisholm J.V., Faircloth K., Linde C.H., et al. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol 2008, 82(6):3147-3153.
18. + T cells directed against NS3. Hepatology 2009, 50(3):707-716.
19. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002, 99(5):3081-3086.
20. Spada E., Mele A., Berton A., Ruggeri L., Ferrigno L., Garbuglia A.R., et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004, 53(11):1673-1681.
21. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997, 71(8):6011-6019.
22. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003, 197(12):1645-1655.
23. Smyk-Pearson S., Tester I.A., Lezotte D., Sasaki A.W., Lewinsohn D.M., Rosen H.R. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis 2006, 194(4):454-463.
24. Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2009, 8(3):333-345.
25. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011, 239(1):99-108.
26. Benmira S., Bhattacharya V., Schmid M.L. An effective HIV vaccine: a combination of humoral and cellular immunity?. Curr HIV Res 2010, 8(6):441-449.